Leg Swelling: Drugs That Cause It and Drugs That Treat It

Why So Many Medications Cause Leg Swelling

Peripheral edema from drugs accounts for a significant share of lower-extremity swelling seen in primary care, with some estimates attributing up to 20% of new-onset bilateral leg edema to medication side effects. The mechanisms vary by drug class, but they converge on two pathways: increased capillary hydrostatic pressure or sodium and water retention at the renal tubule.

Calcium channel blockers (CCBs) illustrate the hydrostatic mechanism clearly. Dihydropyridine CCBs like amlodipine dilate precapillary arterioles without matching venous dilation. This raises capillary pressure and drives fluid into the interstitial space. A pooled analysis of amlodipine trials showed that edema rates climb from roughly 3% at 2.5 mg/day to over 30% at 10 mg/day [1]. At doses used in some refractory hypertension studies, that number exceeds 50%.

The renal retention pathway explains edema from NSAIDs, corticosteroids, and thiazolidinediones. NSAIDs inhibit cyclooxygenase-mediated prostaglandin synthesis in the kidney, reducing renal blood flow and promoting sodium reabsorption. A systematic review published in the BMJ confirmed that NSAID use increases the relative risk of peripheral edema by 1.4 to 2.0 compared with placebo [2]. Corticosteroids activate mineralocorticoid receptors directly. The effect is dose-dependent: patients on prednisone 20 mg/day or higher frequently develop bilateral ankle swelling within the first two weeks.

Not every swollen leg is a drug side effect. But when bilateral, pitting edema appears within days to weeks of starting a new medication, the temporal association is the strongest diagnostic clue.

Calcium Channel Blockers: The Most Common Offenders

Amlodipine is prescribed to over 75 million Americans annually, making it the single most common drug-induced cause of leg swelling in clinical practice. Edema from dihydropyridine CCBs is not an allergic reaction or a sign of heart failure. It is a predictable pharmacologic consequence of arteriolar vasodilation.

The ACCOMPLISH trial (N=11,506) demonstrated that combining amlodipine with benazepril reduced peripheral edema rates compared with amlodipine alone, because ACE inhibitors promote venodilation and reduce the arteriolar-venular pressure gradient [3]. This finding reshaped prescribing: adding an ACE inhibitor or ARB to amlodipine is now a standard strategy when the CCB cannot be discontinued.

Other dihydropyridines carry similar risk. Nifedipine extended-release causes edema in 10-30% of patients. Felodipine sits in a comparable range. Non-dihydropyridine CCBs like diltiazem and verapamil cause edema far less often (under 5%) because they produce less selective arteriolar vasodilation [4].

Practical management steps for CCB-related edema:

1. Reduce the dose if blood pressure targets allow.
2. Add an ACE inhibitor or ARB if not already prescribed.
3. Switch to a non-dihydropyridine CCB or a different antihypertensive class.
4. Avoid adding a diuretic solely to counteract CCB edema, as the swelling is redistributive, not volume-overloaded. Diuretics may cause hypovolemia without resolving the edema.

Gabapentinoids, Thiazolidinediones, and Other Drug Classes

Beyond CCBs, several widely prescribed drug classes produce clinically significant peripheral edema.

Gabapentin and pregabalin. Gabapentinoids cause peripheral edema in 6-12% of patients, according to FDA prescribing information and post-marketing data [5]. The mechanism is incompletely understood but likely involves altered vascular permeability and calcium channel modulation in peripheral vessels. Edema tends to appear within the first 1-3 months of therapy and is more common in patients already taking a CCB.

Pioglitazone. This thiazolidinedione activates PPAR-gamma receptors in the renal collecting duct, increasing sodium reabsorption via epithelial sodium channels. In the PROactive trial (N=5,238), pioglitazone increased edema incidence to 27% versus 17% with placebo and worsened heart failure hospitalizations [6]. The FDA added a black-box warning for use in NYHA Class III-IV heart failure.

NSAIDs. Ibuprofen, naproxen, celecoxib, and other COX inhibitors promote renal sodium retention. Risk is highest in older adults, those with pre-existing renal impairment, and patients on concurrent antihypertensives. The American Heart Association recommends avoiding NSAIDs in patients with established cardiovascular disease partly because of the fluid retention risk [7].

Corticosteroids. Prednisone, dexamethasone, and hydrocortisone cause dose-dependent sodium and water retention. Short courses at low doses (prednisone <10 mg/day) rarely produce visible edema. Prolonged courses above 20 mg/day almost invariably do.

Other notable medications. Insulin at high doses, estrogen-containing oral contraceptives, testosterone replacement therapy (particularly injectable esters), and direct vasodilators like minoxidil and hydralazine each carry documented peripheral edema risk. A review in the American Journal of Medicine catalogued over 60 medications with peripheral edema listed as an adverse effect [8].

Diuretics: First-Line Pharmacologic Treatment for Edema

When leg swelling stems from true volume overload (heart failure, cirrhosis, nephrotic syndrome, or chronic kidney disease), diuretics are the treatment backbone. The choice of agent depends on the underlying cause and the patient's renal function.

Loop diuretics are the workhorse. Furosemide 20-80 mg orally once or twice daily is the most commonly prescribed initial regimen. It blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, producing a potent natriuresis. In acute decompensated heart failure, the DOSE trial (N=308) compared low-dose versus high-dose IV furosemide and found that higher doses produced greater fluid loss and symptom relief, though with a transient rise in creatinine [9]. Bumetanide (1 mg equivalent to furosemide 40 mg) and torsemide (20 mg equivalent to furosemide 40 mg) offer more predictable oral bioavailability. The TRANSFORM-HF trial (N=2,859) found no significant difference in all-cause mortality between torsemide and furosemide at 12 months, though torsemide's longer half-life allows once-daily dosing [10].

Thiazide diuretics like hydrochlorothiazide 12.5-25 mg/day and chlorthalidone 12.5-25 mg/day are effective for mild edema and are often used in combination with loop diuretics for diuretic resistance (sequential nephron blockade). A thiazide added to a loop diuretic can double sodium excretion, but the combination demands close electrolyte monitoring.

Potassium-sparing agents serve dual roles. Spironolactone 25-50 mg/day is the preferred diuretic in cirrhotic ascites with pedal edema. In heart failure with reduced ejection fraction, the RALES trial (N=1,663) showed that spironolactone 25 mg/day reduced mortality by 30% (relative risk reduction) and improved edema control [11]. Eplerenone is an alternative with fewer anti-androgenic side effects.

"In patients with refractory edema, the combination of a loop diuretic with a thiazide-type diuretic and a mineralocorticoid receptor antagonist often succeeds where single agents fail," according to the 2022 AHA/ACC/HFSA Heart Failure Guidelines [12].

When Leg Swelling Is Not About Drugs at All

Drug-related edema is bilateral, pitting, and gravitationally dependent. It does not cause calf pain, redness, or unilateral swelling. Any of those features demand a different workup.

Deep vein thrombosis (DVT) presents with unilateral leg swelling, calf tenderness, and warmth. The Wells score is the standard clinical prediction tool, and compression ultrasonography confirms the diagnosis [13]. DVT requires anticoagulation, not diuretics.

Heart failure causes bilateral edema alongside dyspnea, orthopnea, and elevated jugular venous pressure. Brain natriuretic peptide (BNP) levels above 100 pg/mL or NT-proBNP above 300 pg/mL support the diagnosis. Treatment involves the combination of diuretics, neurohormonal blockade (ACE inhibitors/ARBs, beta-blockers, MRAs, SGLT2 inhibitors), and sodium restriction.

Chronic venous insufficiency (CVI) is the most common non-drug cause of bilateral leg swelling in adults over 50. Valvular incompetence in the deep or superficial venous system leads to venous hypertension and interstitial fluid accumulation. Treatment centers on graduated compression stockings (20-30 mmHg or 30-40 mmHg), leg elevation, and, in selected patients, endovenous ablation.

Nephrotic syndrome, cirrhosis, and hypothyroidism are systemic causes that require specific laboratory workups: urine protein-to-creatinine ratio, hepatic function panel, and TSH, respectively.

"The first step in evaluating bilateral leg edema is a thorough medication review, because removing the offending agent is often the fastest and most effective treatment," states a clinical review in American Family Physician [14].

Practical Algorithm: Evaluating and Managing Drug-Induced Leg Swelling

Start with the medication timeline. If a new drug was started within 1-8 weeks before edema onset, it is the prime suspect.

Step 1: Assess severity. Grade the edema: trace (barely detectable), 1+ (2 mm pit, immediate rebound), 2+ (4 mm pit, 15-second rebound), 3+ (6 mm pit, 60-second rebound), 4+ (8 mm pit, >2 minutes rebound). Measure ankle circumference bilaterally for objective tracking.

Step 2: Exclude dangerous causes. Check for unilateral swelling (DVT), dyspnea at rest (decompensated heart failure), and anuria or oliguria (acute kidney injury). These are emergencies.

Step 3: Review the medication list. Identify any drug from the classes above. Rank by temporal association and known edema rates for that agent.

Step 4: Intervene on the drug. Dose-reduce or discontinue the offending medication when clinically feasible. For amlodipine, consider adding an ACE inhibitor. For gabapentin, assess whether the indication still warrants therapy.

Step 5: Add compression and elevation. Graduated compression stockings at 20-30 mmHg and leg elevation above heart level for 30 minutes three times daily reduce interstitial fluid accumulation regardless of the cause.

Step 6: Use diuretics selectively. Reserve diuretics for true volume-overloaded states. Furosemide is appropriate for heart failure or renal edema. It is less appropriate for CCB-induced edema, where the problem is fluid maldistribution rather than total body fluid excess.

Step 7: Monitor and reassess. Weigh the patient weekly. A stable weight with improving edema suggests the intervention is working. Rising weight despite treatment should prompt re-evaluation for missed diagnoses.

GLP-1 Receptor Agonists and Leg Swelling: What the Data Show

Semaglutide and tirzepatide are now among the most prescribed medications in the United States. Their relationship with peripheral edema is nuanced. GLP-1 receptor agonists do not commonly cause leg swelling. In the STEP-1 trial (N=1,961), peripheral edema was not listed among frequent adverse events for semaglutide 2.4 mg [15].

Weight loss itself may improve pre-existing edema by reducing venous hypertension and intra-abdominal pressure. Patients on GLP-1 agonists who lose significant weight often report improvement in leg swelling that predated their GLP-1 therapy. The SURMOUNT-1 trial (N=2,539) showed 22.5% mean body weight reduction with tirzepatide 15 mg at 72 weeks, and investigators noted improvements in several obesity-related comorbidities including edema-related complaints [16].

SGLT2 inhibitors like empagliflozin and dapagliflozin deserve specific mention. These agents produce osmotic diuresis and natriuresis, and the EMPEROR-Reduced trial (N=3,730) demonstrated a 25% relative risk reduction in heart failure hospitalization with empagliflozin [17]. They are now guideline-recommended for heart failure management, where edema control is a direct therapeutic goal.

Hormone Therapy, TRT, and Fluid Retention

Estrogen-containing hormone replacement therapy (HRT) and testosterone replacement therapy (TRT) both carry peripheral edema as a documented side effect.

Oral estrogen undergoes first-pass hepatic metabolism, increasing hepatic production of angiotensinogen. This activates the renin-angiotensin-aldosterone system (RAAS), promoting sodium retention. Transdermal estradiol bypasses first-pass metabolism and carries a lower risk of fluid retention, which is one reason the Endocrine Society guidelines prefer transdermal delivery in women with cardiovascular risk factors [18].

Testosterone replacement in men can cause fluid retention through several mechanisms: direct mineralocorticoid receptor activation, estradiol-mediated RAAS activation (via aromatization), and erythropoiesis-driven plasma volume expansion. Injectable testosterone esters (cypionate, enanthate) produce supraphysiologic peaks that amplify these effects. The Endocrine Society's 2018 TRT guidelines recommend monitoring for peripheral edema, especially in men with congestive heart failure [19]. Dose adjustment or switching to daily transdermal testosterone may mitigate the swelling.

Ankle edema in a patient on TRT should prompt measurement of hematocrit (erythrocytosis above 54% requires dose reduction or phlebotomy) and assessment for sleep apnea, which is both a cause and consequence of fluid retention.